The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com

PARTNER NEWS:

Tue, Jan 21, 8:30 AM, Zacks
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Here are 5 stocks added to the Zacks 1 Rank ( strong buy ) List for Tuesday

Array BioPharma Inc. (ARRY)

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients with cancer. Co.'s wholly-owned clinical stage drugs include: ARRY-520, a Kinesin spindle protein inhibitor for multiple myeloma, ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes, ARRY-797, a p38 inhibitor for pain and ARRY-502, a CRTh2 antagonist for asthma. In addition, Co. has partner-funded clinical programs, including two MEK inhibitors in Phase 2 or 3 clinical trials, MEK162 with Novartis and selumetinib with AstraZeneca. Co. also has a portfolio of proprietary and partnered preclinical drug discovery programs.

Company Name:  Array BioPharma Inc.
Website:  www.arraybiopharma.com
Sector:  Biotechnology
Number of ETFs Holding ARRY:  17
Total Market Value Held by ETFs:  $32.14M
Total Market Capitalization:  $482.00M
% of Market Cap. Held by ETFs:  6.67%
April 18, 2014    7:15 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade ARRY Now:



Strong Buy (4.00 out of 4)
93rd percentile
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Array BioPharma Inc. (ARRY) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.